We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Super DNA Sequencing Facility Planned

By Biotechdaily staff writers
Posted on 19 Aug 2002
J. More...
Craig Venter has announced plans to create a next-generation high-throughput DNA sequencing facility in Rockville, MD (USA). He will be aided by The Institute for Genomic Research (TIGR), the Institute for Biological Energy Alternatives (IBEA), and The Center for the Advancement of Genomics (TCAG), all of which he founded. All are not-for-profit organizations supported by the J. Craig Venter Science Foundation, which will provide administrative support and coordinate policy and research activities. The new facility will also be not-for-profit and will make information freely available to researchers, not selling it as Celera Genomics did.

As the head of Celera Genomics, Dr. Venter was responsible, along with a US government group, for completing the first sequencing of the human genome. The results have enabled researchers to make many new medical findings and develop new drugs. However, as Dr. Venter points out, even though the cost of sequencing a species has rapidly declined from billions to millions of dollars, there is still a need to substantially reduce these costs even further so more people can benefit from the great promise that genomics holds.

TIGR, TCAG, and IBEA are building a facility to rapidly sequence and analyze genomes in a more cost-effective manner. The new facility will utilize the latest developments in automated DNA sequencing, supercomputing, networking, and high-performance storage technologies. The center will also house a research and development laboratory that will explore advanced technologies from a variety of vendors. Research projects include continuation of ongoing biologic energy research that is seeking new organisms and analyzing known organisms that metabolize carbon or create hydrogen. Another project planned will be to use sequencing to better understand ethno-geographic differences among populations.

"As we continue to explore the implications of individual genetic sequences, this information needs to rapidly become an integral part of medical care and preventive medicine,” said Dr. Venter. "One of our goals in building this facility is to make genomic sequencing of the six billion people on this planet technologically feasible so that everyone can benefit and be empowered by this information.”




Related Links:
TIGR

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.